NEWARK, N.J., Feb. 25, 2013 /PRNewswire/ -- Mark Lowenthal, President and CEO of BioNeutral Group, Inc. (OTCBB: BONU), a specialty technology-based life-science company, announced today that following an extensive product development and testing period, the initial reception of its products in the marketplace has far exceeded the Company's initial expectations.
In a letter to shareholders, Mr. Lowenthal stated, "After only six weeks in the marketplace, it now appears that our efforts are beginning to bear fruit. To date we have called on approximately 75 potential customers across a wide variety of trade classes in the relevant Health and Industrial markets and we're happy to say that the reception to our product offerings, both Ygiene™ 206 and Ogiene™ have far exceeded our expectations. Over two thirds of the accounts we called on in the healthcare and life sciences related markets were interested in meeting with us, and to date, over 50% of those proceeded to initiate trials of our products with many more trials pending. In the Industrial markets, we were equally well received with "across the board" interest from the full spectrum of market participants, i.e. end users, distributors, wholesalers and independent manufactures' in markets as diverse as Sanitation and Janitorial services, Mold Remediation and agriculture both here at home as well as abroad."
In his announcement, Mr. Lowenthal went on to say, "much still needs to be accomplished. Our meetings are early ones. Trials, while going well, need to be completed and even more initiated. However, it is becoming increasingly evident to us that our products meet a "need" in the marketplace that we are fast becoming increasingly able to meet. In this regard, we have begun taking initial stocking orders with a growing amount anticipated, although as always there can be no assurance, over the next several months. While at thi
|SOURCE BioNeutral Group, Inc.|
Copyright©2012 PR Newswire.
All rights reserved